Gosset Ownership
Private
Employees
~10
Therapeutic Areas
Stage
Preclinical
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Aakha Biologics General Information
Developing novel antibody drugs that can attract immune cells to tumors and activate them to kill the tumor. Recently received $2.95 million in non-dilutive funding from CPRIT and NCI to accelerate IND-enabling studies[1][6].
Contact Information
Drug Pipeline
AHA-1031
Pre-clinicalKey Partnerships
Alloy Therapeutics, Wheeler Bio
Aakha Biologics Funding
No funding data available
To view Aakha Biologics's complete valuation and funding history, request access »